Braveheart Bio, Inc. (BRVE) Investment Research Dashboard
About Braveheart Bio, Inc. (BRVE) stock analysis
Get live BRVE stock price $25.18, comprehensive Braveheart Bio, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time BRVE stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquarter...
Company Information
- CEO
- Travis Murdoch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- N/A
Contact Information
- Website
- http://www.braveheart.bio
- Address
- One Letterman Drive, Building A, Suite A4-300
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Listed on major US exchange (NASDAQ) providing liquidity and transparency
✓ Lower volatility stock (Beta: 0.00) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Braveheart Bio, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Braveheart Bio, Inc.
- ⚠Investors should consider how Braveheart Bio, Inc. fits within their overall portfolio allocation
Market Cap
1.78B
Beta
0.00
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
75/100 ⭐⭐⭐⭐⭐
- Overall
- -0.6%
- NYSE
- -0.8%
- NASDAQ
- -0.4%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Energy | -0.5% | +4.6% | +2.9% | 18.9 | 84/100⭐⭐⭐⭐⭐ |
| Financial Services | +0.1% | -0.2% | +4.7% | 19.5 | 77/100⭐⭐⭐⭐⭐ |
| Healthcare | -0.6% | +2.1% | +2.9% | 23.5 | 75/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | +0.5% | +2.7% | +2.6% | 29.1 | 64/100⭐⭐⭐⭐ |
| Communication Services | +1.1% | +0.8% | +0.9% | 20.9 | 57/100⭐⭐⭐⭐ |
| Industrials | -0.3% | +2.9% | +1.0% | 31.5 | 52/100⭐⭐⭐ |
| Technology | +1.2% | -0.6% | +1.2% | 45.3 | 41/100⭐⭐⭐ |
| Real Estate | +0.4% | +0.7% | -1.9% | 27.8 | 34/100⭐⭐ |
| Basic Materials | +0.0% | -0.5% | -0.7% | 25.0 | 32/100⭐⭐ |
| Consumer Cyclical | +0.5% | +0.5% | -2.0% | 45.5 | 21/100⭐ |
| Utilities | -0.7% | -0.7% | -8.8% | 24.5 | 12/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-08-13.